세계의 박테리오파지 시장 : 부문별 예측(2025-2030년)

The Bacteriophage Market was valued at USD 47.74 million in 2023, expected to reach USD 50.15 million in 2024, and is projected to grow at a CAGR of 5.26%, to USD 68.35 million by 2030.

Bacteriophages, viruses that infect and lyse specific bacteria, have garnered attention for their potential in combating antibiotic-resistant infections and as precision tools in microbiome modulation. With an escalating need for alternative antibacterial treatments, the bacteriophage market is set to expand, propelled by the necessity to address antibiotic resistance crises and growing interest in personalized medicine. Applications extend across healthcare, agriculture, and food safety, where bacteriophages are used to enhance crop protection and prevent food spoilage. The end-use scope predominantly covers hospitals, clinics, research institutes, and agricultural sectors. Key growth factors include increasing awareness of phage therapy, advancements in genetic engineering which allow for tailored phage solutions, and regulatory support in several countries easing market entry. However, the market faces limitations such as high costs of development, complex regulatory frameworks for approval, and limited awareness among healthcare professionals. Additionally, phages' specificity, while an advantage, can also pose a challenge as it necessitates tailored solutions for each bacterial strain. The latest potential opportunities lie in the development of synthetic phages and combination therapies, creating partnerships with agriculture sectors for phage-based biopesticides, and expanding phage libraries to cover a broader range of infectious pathogens. Recommendations include investing in targeted marketing campaigns to increase acceptance among medical professionals, fostering collaborations with biotechnology firms to streamline production, and pursuing multi-regional partnerships to diversify application portfolios. Despite challenges, areas like synthetic biology advancements and delivery system innovations present ripe opportunities for differentiation. Research into phage-host interactions and optimizing phage stability could further enhance commercial viability. Understanding regional market variations and regulatory landscapes will be crucial for capitalizing on local opportunities, while continuous innovation in delivery mechanisms and phage formulations offer the best avenues for business growth in this burgeoning market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bacteriophage Market

The Bacteriophage Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of antibiotic-resistant bacterial infections driving demand for bacteriophage therapy
  • Rising investments in research and development for bacteriophage applications in healthcare
  • Growing public awareness and acceptance of bacteriophage as a viable alternative to antibiotics
  • Expansion of bacteriophage application in food safety and agricultural productivity enhancement
• Market Restraints
  • Limited awareness and acceptance of bacteriophage therapy among healthcare professionals and patients
  • High competition from established antibiotic treatments limiting bacteriophage therapy adoption
• Market Opportunities
  • Collaborating with pharmaceutical companies to accelerate bacteriophage drug development pipelines
  • Implementing bacteriophage use in veterinary medicine to improve animal health and food production
  • Utilizing bacteriophage therapies in combination with traditional antibiotics for synergistic effects
• Market Challenges
  • Lack of standardized protocols for bacteriophage therapy impeding clinical adoption and consistency
  • High specificity of bacteriophages requiring individualized development for different bacterial strains

Porter's Five Forces: A Strategic Tool for Navigating the Bacteriophage Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bacteriophage Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bacteriophage Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bacteriophage Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bacteriophage Market

A detailed market share analysis in the Bacteriophage Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bacteriophage Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bacteriophage Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bacteriophage Market

A strategic analysis of the Bacteriophage Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bacteriophage Market, highlighting leading vendors and their innovative profiles. These include Adaptive Phage Therapeutics, AmpliPhi Biosciences Corporation, Armata Pharmaceuticals Inc., ContraFect Corporation, CYTOO S.A., Eligo Bioscience, EnBiotix Inc., Fixed-Phage Limited, Intralytix Inc., iNtRON Biotechnology, Locus Biosciences Inc., Micreos BV, Optipharm Co. Ltd., Phage International Inc., Phagelux Inc., Phagomed Biopharma GmbH, Pherecydes Pharma, Phico Therapeutics Ltd., Sexton Biotechnologies, and TechnoPhage SA.

Market Segmentation & Coverage

This research report categorizes the Bacteriophage Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Lysogenic and Lytic.
• Based on Product, market is studied across Phage Diagnostic Products, Phage Research Tools, and Phage Therapy Products.
• Based on Form, market is studied across Liquid and Solid.
• Based on Delivery Mode, market is studied across Injectable, Oral, and Topical.
• Based on Application, market is studied across Agricultural, Diagnostic, and Therapeutic. The Therapeutic is further studied across Human Therapeutic and Veterinary Therapeutic.
• Based on End-User, market is studied across Hospitals and Clinics, Pharmaceutical Companies, and Research Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of antibiotic-resistant bacterial infections driving demand for bacteriophage therapy
    • 5.1.1.2. Rising investments in research and development for bacteriophage applications in healthcare
    • 5.1.1.3. Growing public awareness and acceptance of bacteriophage as a viable alternative to antibiotics
    • 5.1.1.4. Expansion of bacteriophage application in food safety and agricultural productivity enhancement
  • 5.1.2. Restraints
    • 5.1.2.1. Limited awareness and acceptance of bacteriophage therapy among healthcare professionals and patients
    • 5.1.2.2. High competition from established antibiotic treatments limiting bacteriophage therapy adoption
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborating with pharmaceutical companies to accelerate bacteriophage drug development pipelines
    • 5.1.3.2. Implementing bacteriophage use in veterinary medicine to improve animal health and food production
    • 5.1.3.3. Utilizing bacteriophage therapies in combination with traditional antibiotics for synergistic effects
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of standardized protocols for bacteriophage therapy impeding clinical adoption and consistency
    • 5.1.4.2. High specificity of bacteriophages requiring individualized development for different bacterial strains
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Bacteriophage Market, by Type

• 6.1. Introduction
• 6.2. Lysogenic
• 6.3. Lytic

7. Bacteriophage Market, by Product

• 7.1. Introduction
• 7.2. Phage Diagnostic Products
• 7.3. Phage Research Tools
• 7.4. Phage Therapy Products

8. Bacteriophage Market, by Form

• 8.1. Introduction
• 8.2. Liquid
• 8.3. Solid

9. Bacteriophage Market, by Delivery Mode

• 9.1. Introduction
• 9.2. Injectable
• 9.3. Oral
• 9.4. Topical

10. Bacteriophage Market, by Application

• 10.1. Introduction
• 10.2. Agricultural
• 10.3. Diagnostic
• 10.4. Therapeutic
  • 10.4.1. Human Therapeutic
  • 10.4.2. Veterinary Therapeutic

11. Bacteriophage Market, by End-User

• 11.1. Introduction
• 11.2. Hospitals and Clinics
• 11.3. Pharmaceutical Companies
• 11.4. Research Institutions

12. Americas Bacteriophage Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Bacteriophage Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Bacteriophage Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adaptive Phage Therapeutics
• 2. AmpliPhi Biosciences Corporation
• 3. Armata Pharmaceuticals Inc.
• 4. ContraFect Corporation
• 5. CYTOO S.A.
• 6. Eligo Bioscience
• 7. EnBiotix Inc.
• 8. Fixed-Phage Limited
• 9. Intralytix Inc.
• 10. iNtRON Biotechnology
• 11. Locus Biosciences Inc.
• 12. Micreos BV
• 13. Optipharm Co. Ltd.
• 14. Phage International Inc.
• 15. Phagelux Inc.
• 16. Phagomed Biopharma GmbH
• 17. Pherecydes Pharma
• 18. Phico Therapeutics Ltd.
• 19. Sexton Biotechnologies
• 20. TechnoPhage SA